Grow your wealth
your way.

Bioverge offers diverse ways for our clients to invest: through Deal-by-Deal opportunities, Bioverge Access Funds, and Bioverge Access Funds. Sign up to view exclusive deals on the Bioverge platform.

A vital component of premier portfolios.

Investment managers and institutional investors routinely use venture capital to diversify outside of stocks and bonds. Additionally, investing in healthcare venture capital provides the following benefits:

Portfolio Diversification

The average institutional investor has up to 30% of their portfolio in alternative assets, compared with 5% for individuals, despite the benefits of diversification across asset classes.

With Bioverge, you can diversify across technology types, disease areas, and stage of development.

Enhanced Returns

As an asset class, venture capital has generated attractive risk-adjusted returns over time, which can help you achieve your long-term financial goals.

The median net IRR for early-stage healthcare venture capital funds is 19.2%, suggesting these investments have a high potential for returns.1

Reduced Volatility

Venture capital does not typically suffer from daily price fluctuations. Its low correlation to both stock and bond markets can provide portfolio stability.

Tax Advantages

Investments may qualify for long-term capital gains tax treatment, and QSBS tax benefits, which can provide up to a 100% break on capital gains taxes.

Institutional healthcare venture capital experience for individual investors.

Bioverge empowers investors to invest in high-quality companies vetted by rigorous, institutional due diligence alongside us and other top-tier co-investors, at the same terms

Data-Driven Investing

Bioverge is leveraging an artificial intelligence-driven diligence process to select the most compelling early-stage healthcare investment opportunities

Simplified Access to Premier Investments

Invest in a healthcare venture capital fund that reduces barriers to institutional-quality assets more efficiently and with low fees.

Invest alongside top-tier venture funds, at the same terms.

Simplified Access to Premier Investments

Invest in a healthcare venture capital fund that reduces barriers to institutional-quality assets more efficiently and with low fees.

Invest alongside top-tier venture funds, at the same terms.

Low Fees, Low Friction

Bioverge offers investment access and typically charges lower fees than most venture capital firms.

1 Source: Cambridge Associates,  Back
Important Disclosures
Private Securities
Investments in private offerings are speculative and involve a high degree of risk. Investments in private offerings are not bank deposits and therefore are not insured by the FDIC or guaranteed by any other party. Investors must be qualified as an accredited investor to participate in private offerings and you may be required to verify your status as an accredited investor. No securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information or materials provided by or through us.
Not Advice
This communication is not to be construed as investment, tax, or legal advice in relation to the relevant subject matter; investors must seek their own legal or other professional advice before making any investment to determine whether an investment is suitable for them.
Performance Not Guaranteed
Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections are not guaranteed and may not reflect actual future performance.
Risk of Loss
All investments involve a high degree of risk and may result in partial or total loss of your investment.
Liquidity Not Guaranteed
Investments offered by Bioverge are illiquid and there is never any guarantee that you will be able to exit your investments on the Secondary Market or at what price an exit (if any) will be achieved.
Not an Offer to Sell or Solicitation to Buy
The information presented on this Website does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Bioverge. Any such offer would only be made through of a prospectus, private placement memorandum, subscription agreement or similar documents. This Website is subject to material updating, revision and further amendment.
Conduct Your Own Due Diligence
This information is not intended to provide the sole basis for your evaluation of Bioverge. You should conduct your own due diligence of Bioverge and independently verify the information contained below before proceeding further with any investment in or other transaction with Bioverge. Our officers will make themselves available to answer any questions that you may have regarding our company, its business, operations and prospects should you decide to proceed further with an investment or other transaction with Bioverge.
Forward Looking Statements
The information set forth below includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations. Back